Tenofovir alafenamide or tenofovir disoproxil fumarate in pregnancy to prevent HBV transmission: Maternal ALT trajectory and infant outcomes
Journal
Liver international : official journal of the International Association for the Study of the Liver
Date Issued
2024-03-08
Author(s)
Chang, Chin-Hao
Lai, Ming-Wei
Tsai, Ming-Chieh
Mu, Shu-Chi
Wen, Wan-Hsin
Hu, Rui-Ting
Huang, Chun-Pin
Hu, Kuang-Chun
Chen, Chie-Pein
Lee, Chyi-Long
Chien, Rong-Nan
Abstract
The use of antiviral agents, specifically tenofovir disoproxil fumarate (TDF), in pregnant women to prevent mother-to-child HBV transmission is a key step towards hepatitis elimination. However, data on using tenofovir alafenamide (TAF) is insufficient. The frequent occurrence of postpartum ALT flares may impact the clinical implementation.
Subjects
HBV immunization; HBeAg; antiviral therapy; children; hepatitis B virus; mother-to-infant transmission; nucleoside analogue; pregnancy; pregnant women
Type
journal article